The case in front of me: 7.5 mg · liraglutide.
This is one of those things that everyone repeats and nobody derives.
This matters practically, not just academically, because it changes what I would do next.
Is the standard explanation correct, and if so, what is the evidence for it?
Two administrations of 3.75 mg instead of one of 7.5 mg — the same 7.5 mg a week either way. Total weekly exposure is unchanged; what changes is the peak-to-trough ratio, and for an agent with a half-life measured in days the trough barely moves because the dosing interval is already short relative to it. The arithmetic is the easy part: 7.5 ÷ 2 = 3.75. Whether it is worth doing is a pharmacokinetic question, and nothing here is medical advice.
Start with the half-life. For an agent with a one-week half-life, weekly dosing already produces a nearly flat profile and splitting changes very little.
Each additional injection is an additional stopper entry, an additional needle and an additional opportunity to introduce contamination into a preparation that has no release testing behind it.
| Configuration | Dead volume | Loss at 5 mg/mL | Over 20 draws |
|---|---|---|---|
| Fixed-needle insulin syringe | 3–5 µL | 15–25 µg | 0.3–0.5 mg |
| Low-dead-space, detachable | <2 µL | <10 µg | <0.2 mg |
| Standard luer-lock + 30G | 35–60 µL | 175–300 µg | 3.5–6 mg |
| Luer-lock + 21G drawing needle | 70–100 µL | 350–500 µg | 7–10 mg |
For a thirteen-hour half-life agent dosed daily, τ/t½ is about 1.8 and the swing is nearly fourfold, which is why the daily agents feel peakier and why splitting them would have more effect.
Published half-lives for the agents in this class range from about thirteen hours to about a week, which is the range over which the answer changes.
More injections means more handling risk, and that cost is certain while the benefit is not.
If you cannot read half the dose accurately, you cannot split it accurately.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswer first: splitting a weekly dose into smaller more frequent doses reduces peak-to-trough variation, and whether that helps depends entirely on the half-life of the agent.
Accumulation to steady state takes four to five half-lives regardless of how the dose is divided. Splitting does not shorten it and does not change the average exposure.
To be exact about it, halving a dose accurately requires the reading resolution to support it. A 10-unit dose split into two 5-unit doses is at the coarse end of any barrel.
No trial in this class has evaluated a split schedule against the licensed one, so any comparison is anecdotal.
Work out 2^(τ/t½) for your agent before arguing about this. It usually settles it.
Answering this needs the specific agent, because the answer for a thirteen-hour half-life and a one-week half-life are opposite.
Splitting that same weekly dose into two half-doses at 3.5-day intervals gives τ/t½ = 0.5 and a peak-to-trough ratio of about 1.41. The profile is flatter, and the difference between a 2-fold and a 1.4-fold swing is not obviously perceptible.
Reported tolerability improvements with splitting may reflect the smaller absolute amount arriving at once rather than the exposure profile, which is a different mechanism and is not well characterised.
The peak-to-trough relationship 2^(τ/t½) is standard pharmacokinetics for a one-compartment model with first-order elimination and is the correct tool for this question.
For a weekly half-life, weekly dosing is already flat. Splitting buys very little.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.